Naslov
HPV vaccine and males

Autori
Skerlev, Mihael

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Izvornik
Proceedings of the 6th Spring Symposium of the European Academy of Dermatology and Venereology / D.Forsea, C. Popescu, G.S. Tiplica - Bukurešt : Journal of the European Academy of Dermatology and Venereology (JEADV), 2009

Skup
6th Spring Symposium of the European Academy of Dermatology and Venereology

Mjesto i datum
Bukurešt, Rumunjska, 24.04.2009. - 25.04.2009

Vrsta sudjelovanja
Plenarno

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
HPV; males; HPV vaccine

Sažetak
Human papillomavirus (HPV)-associated genital pathology represents one of the major problems among STIs mostly due to the high recurrence rate, difficult eradication and oncogenic potential. Besides, the young, sexually active population in the generative period is mostly affected. Anogenital HPV infections are the most frequently diagnosed STIs of viral origin. In general, it can be postulated that, over the last decade, the oncogenic properties of HPVs have been intensively studied. Significant progress has been achieved in the investigation of the HPV prevention. More than 35 types of HPV infect the genital tract ; types 16 and 18 inducing about 70% of cervical cancer and high-grade cervical (and not only cervical) intraepithelial neoplasia (CIN), and HPV 6 and 11 causing 90% of anogenital warts. A prophylactic vaccine that targets these types should thus substantially reduce the burden of HPV-associated clinical diseases. The results of the most recent studies have clearly shown that a quadrivalent HPV vaccine (6, 11, 16, and 18) was generally well tolerated, induced high-titres of serum antibodies to HPV types, and effectively prevented acquisition of infection and clinical disease caused by common HPV types. Since HPV is transmitted by sexual intercourse, managing both partners is necessary in order to eliminate the virus in the population. Approaches to this include prophylactic vaccines such as quadrivalent HPV vaccine for both men and women. This should be the only way to significantly decrease the numbers of infected persons. The recent introduction of the HPV vaccine has ushered in new hope of substantially reducing global prevalence of HPV disease. Ultimately, within the spectrum of therapeutic options for condylomata, no method is really superior to others ; recurrences occurred in 30-70% of cases. We definitely need the HPV vaccination programme to get rid of one of the oldest and up to now unsolved problems of mankind. Vaccine-induced immunogenicity in men is similar to that in women, and there are indirect benefits to women with male vaccination. The results of the most recent clinical efficacy studies of the quadrivalent HPV vaccine in men have clearly shown that among 1, 390 vaccine subjects and 1, 400 placebo subjects, efficacy against persistent infection with HPV 6/11/16/18 was 85.6%. Efficacy against persistent infection with individual HPV types 6, 11, 16, and 18 was 88.0%, 93.4%, 78.7% and 96.0% respectively. In summary, the quadrivalent HPV vaccine has been also proven to be effective in decreasing the incidence and persistence of infection with HPV 6/11/16/18 in a population of young men aged 16-26 years. Thus, the role of quadrivalent HPV vaccine in preventing genital warts in men will definitely need to be (re)emphasized. It can be concluded that, in this very moment, there is a need for a coordinated effort of patients, parents, health professionals, hospitals, and policymakers to ensure successful implementation of vaccination programs for both women and men.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita

Napomena
Focus Session: M.Skerlev: HPV vaccine and males

POVEZANOST RADA